Moneycontrol PRO
Check Credit Score
Check Credit Score
HomeNewsBusinessStocks

Hold Glenmark Pharmaceuticals; target of Rs 900: Axis Direct

Axis Direct has recommended hold rating on Glenmark Pharmaceuticals with a target price of Rs 900 in its research report dated August 16, 2016.

August 17, 2016 / 04:25 PM IST
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Axis Direct's research report on Glenmark Pharmaceuticals

Glenmark's (GNP) Q1 EBITDA growth (up 5% YoY) was in line with our estimate. Reported PAT was 17% higher than our estimatebut in-line when adjusted for MTM^ forex gain. Reported revenue growth of 18% YoY was led by US (18% YoY), India(10%), RoW (23%) and API (42%).Gross margin decline of 269 bps YoY coupled with spike in staff costs (30% YoY, led by R&D staff increase) pulled EBITDA margin down 230 bps to 19.5%. While we expect strong revenue growth (ex-gZetia) in US (16% in FY16-18 vs. 6% in FY14-16) to improve the margin, we remain cautious on Venezuela repatriation issues (~USD 45mn outstanding, paired with negligible sales) and increasing debt. We tweak our estimates but maintain HOLD with revised TP of Rs 900(19x FY18E coreEPS+ Rs 6 for novel R&D project + Rs 19 for one-time gZetia exclusivity) vs. Rs 915 earlier.
For all recommendations, click here Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

first published: Aug 17, 2016 04:25 pm

Discover the latest business news, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347